Trial Section
Home / Trial Section / Clinical Trial| Indication | Department | Study Title | Study Phase | Investigator | Contact Person | Status |
|---|---|---|---|---|---|---|
| Breast Cancer | Breast Oncology and Surgery | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase III | Ming-Feng Hou | 謝淑娟 | On-going |
| Breast Cancer | Breast Oncology and Surgery | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2?) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH?]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Phase III | Ming-Feng Hou | 李安婷 | On-going |
| Breast Cancer | Breast Oncology and Surgery | A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) | Phase III | Ming-Feng Hou | 謝淑娟 | On-going |
| Breast Cancer | Breast Oncology and Surgery | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2) | Phase III | Ming-Feng Hou | 黃映瑄 | On-going |
| Breast Oncology and Surgery | A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05) | -- | Ming-Feng Hou | 謝淑娟 | On-going | |
| Breast Cancer | Breast Oncology and Surgery | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER | Phase III | Ming-Feng Hou | 李安婷 | On-going |
| Breast Oncology and Surgery | A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with HER2 Low Breast Cancer (Cornerstone-001) | Phase II | Ming-Feng Hou | 黃映瑄 | On-going | |
| Breast Cancer | Breast Oncology and Surgery | postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy | Phase III | Ming-Feng Hou | 黃映瑄 | On-going |
| Breast Cancer | Breast Oncology and Surgery | EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers | Phase I | Ming-Feng Hou | 謝淑娟 | On-going |
| Breast Cancer | Breast Oncology and Surgery | A randomized, multicenter, double-blind phase 3 study of amcenestrant (SAR439859) plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease | Phase III | Ming-Feng Hou | 李安婷 | Completed |
← Please slide to the left for more information